HKSE - Delayed Quote HKD

Keymed Biosciences Inc. (2162.HK)

Compare
43.650 -0.700 (-1.58%)
At close: 3:59 PM GMT+8
All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-303,620.000
-303,620.000
-401,934.000
-214,637.000
-119,361.000
Investing Cash Flow
468,203.000
468,203.000
-645,586.000
-2,035,879.000
-113,067.000
Financing Cash Flow
72,131.000
72,131.000
-8,059.000
3,638,376.000
7,397.000
End Cash Position
851,029.000
851,029.000
604,070.000
1,520,619.000
199,409.000
Capital Expenditure
-382,610.000
-382,610.000
-279,549.000
-172,858.000
-19,896.000
Issuance of Capital Stock
--
--
--
3,759,752.000
3,475.000
Issuance of Debt
360,000.000
360,000.000
89,950.000
--
--
Repayment of Debt
-72,645.000
-72,645.000
--
--
-5,614.000
Repurchase of Capital Stock
-32,901.000
-32,901.000
-51,135.000
-58,154.000
--
Free Cash Flow
-686,230.000
-686,230.000
-681,483.000
-387,495.000
-139,257.000
12/31/2020 - 7/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers